| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K03536150 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.0008 |
| mRNA | NSC-207895 | GDSC1000 | pan-cancer | AAC | 0.11 | 0.0008 |
| mRNA | dabrafenib | GDSC1000 | pan-cancer | AAC | -0.1 | 0.0008 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | -0.11 | 0.0008 |
| mRNA | QL-XI-92 | GDSC1000 | pan-cancer | AAC | 0.1 | 0.0008 |
| mRNA | HG-6-64-1 | GDSC1000 | pan-cancer | AAC | -0.12 | 0.0008 |
| mRNA | VX-680 | CTRPv2 | pan-cancer | AAC | 0.4 | 0.0009 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | -0.19 | 0.001 |
| mRNA | Bleomycin | GDSC1000 | pan-cancer | AAC | -0.12 | 0.001 |
| mRNA | ISOX:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.11 | 0.001 |